Increasing payers benefits from parallel trade: Observations from Scandinavia and policy proposals for Europe
Our case studies from three Scandinavian countries have shown that parallel trade is not lowering drug expenditures to the same extent in all countries. While relative price advantages of parallel traded drugs are sizeable in Sweden, they are very low in Norway.
KeywordsPolicy Proposal Medicine Control Agency Parallel Trade Durable Consumer Good Price Convergence
Unable to display preview. Download preview PDF.